Description

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, Reseacher projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. Researcher also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Seasonal Influenza Vaccine Market Size, Country Outlook ...

Seasonal Influenza Vaccine Market is expected to reach ... by the year end of 2022. Market growth can be ... influenza vaccines, ...Read more

Global Influenza Vaccine Market Outlook 2022 - Research ...

... they may be classified as strains to be updated in seasonal vaccines. ... Global Influenza Vaccine Market Outlook 2022 6.1 Current Market Overview and ...Read more

PharmaPoint: Seasonal Influenza Vaccines - Global Drug ...

GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market ... trivalent influenza vaccines currently ...Read more

Seasonal Influenza Vaccines Market 2022 - PdfSR.com

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market ..Read more

These presentations are classified and categorized, so you will always find everything clearly laid out and in context.
You are watching What is research?? presentation right now. We are staying up to date!